INTRODUCTION AND OBJECTIVE: Cancer is defined as a set of diseases characterized by the disordered growth of cells that can affect various organs and tissues. It is nowadays the world second leading cause of mortality, surpassed only by cardiovascular diseases. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide and it is expected that by 2050, there will be around 35 million new cases per year. In addition to the traditional therapeutic approaches, such as chemotherapy, radiotherapy and surgery, alternative therapies must be researched and developed to enhance patient’s quality life. One alternative is the use of oncolytic viruses (OVs) that can induce tumor cell death by viral infection trough cell lysis. The Talimogene laherparepvec (T-VEC) was the first OV developed and approved to be use in clinical practice by the Food and Drug Administration (FDA) and is based on the HSV-1 genome. One way to potentialize the effects of cell death in the context of OVs is to insert therapeutics genes along with the virus infection. In this project, we constructed OVs armed with the pro-apoptotic TRAIL protein, a well-known protein capable of inducing apoptosis in the tumor while sparing non-tumor cells. MATERIAL AND METHOD: In this study we used two different methodologies to construct our oncolytic viruses. In the first one, we used the Escherichia coli strain SW102 as one step homologous recombination (HR) containing the Bacterial Artificial Chromosome (BAC) as HSV-1 genome (strain 17+). And in the second one, we used two steps of HR to remove any traces of antibiotic selection mark genes in the strain GS1783. Restriction enzymes were used as screening to check the DNAs (plasmids and BACs) integrity and the cloning procedures along with sequencing. An OV expressing the EGFP gene was used as positive control for transfections and virus amplification in Vero cell line. TRAIL protein expression was observed by Western Blot technique. RESULTS AND CONCLUSION: We constructed two types of recombination oncolytic viruses in two different loci. One in a specific locus to further observe the attenuation effects of an HSV-1 gene deletion and the other in the region of locus UL55-UL56, same backbone of the T-VEC. The confirmation of the HR target regions inside the BAC was positive by screening with restriction enzymes and with Sanger sequencing. We also validated all the transfection and virus amplification by fluorescence along with the positive control HSV-1 EGFP and follow to detect the expression of the TRAIL protein by Western Blot. Regardless of the Ovs construction and characterization performed, further analyses need to be conducted to evaluate the cytotoxic effects mainly related with capacity to induce cell death in the cancer context.